Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Bausch Health Companies Inc. is a global pharmaceutical company focused on developing, manufacturing, and marketing branded and generic prescription drugs, over-the-counter products, and medical devices. The company operates primarily in the pharmaceuticals and medical aesthetics industries, serving healthcare providers, hospitals, pharmacies, and patients across multiple therapeutic areas. Its revenue is driven mainly by branded prescription products, with additional contributions from consumer health products and ophthalmology devices.
The company’s core portfolio spans gastroenterology, ophthalmology, dermatology, neurology, and aesthetics, with several established brands generating recurring revenue. Bausch Health is positioned as a diversified specialty pharmaceutical company with strong brand recognition in niche therapeutic categories. Originally founded in 1833 as Bausch & Lomb, the company evolved through decades of expansion and acquisitions, later operating as Valeant Pharmaceuticals before rebranding as Bausch Health Companies Inc. in 2018 to reflect a renewed strategic focus on sustainable growth, compliance, and operational discipline.
Business Operations
Bausch Health operates through several primary business segments, including Bausch + Lomb, Salix Pharmaceuticals, International, and Diversified Products. These segments collectively generate revenue through the sale of prescription drugs, eye health products, contact lenses, surgical devices, and consumer healthcare items. The Salix Pharmaceuticals unit is a key revenue driver, focusing on gastroenterology products, while Bausch + Lomb represents a major ophthalmology platform spanning pharmaceuticals, vision care, and surgical products.
The company maintains both domestic and international operations, with manufacturing, research, and commercial infrastructure across North America, Europe, Latin America, and parts of Asia. Bausch Health controls a broad portfolio of intellectual property, manufacturing facilities, and product licenses. It operates through numerous wholly owned subsidiaries and maintains commercial partnerships for distribution and product development in select markets, while retaining centralized oversight of strategy, compliance, and capital allocation.
Strategic Position & Investments
Bausch Health’s strategic direction emphasizes deleveraging, investment in core brands, and selective innovation within established therapeutic areas. The company has prioritized organic growth initiatives, including lifecycle management of key products, expansion of ophthalmology offerings, and targeted investments in research and development. A significant strategic milestone was the partial initial public offering of Bausch + Lomb, which operates as a publicly traded subsidiary while remaining majority-owned.
The company’s investment strategy also includes disciplined portfolio management, divestitures of non-core assets, and reinvestment into high-margin, durable product categories. Bausch Health continues to focus on emerging technologies within eye health, gastroenterology therapeutics, and dermatology, while maintaining a cautious approach to large-scale acquisitions. Where public disclosures vary on future separation or monetization plans, data is inconclusive based on available public sources.
Geographic Footprint
Bausch Health is headquartered in Canada, with significant operational and commercial presence in the United States, which represents its largest market. The company has an extensive international footprint across Europe, Latin America, Asia-Pacific, and parts of Africa, serving both developed and emerging markets through local subsidiaries and distribution partners.
Its global infrastructure includes manufacturing plants, research centers, and sales organizations spread across multiple continents, enabling localized production and regulatory compliance. International operations contribute a meaningful portion of revenue and provide geographic diversification, particularly in ophthalmology and consumer health products, where brand penetration is strong outside North America.
Leadership & Governance
Bausch Health is led by an experienced executive team with backgrounds in pharmaceuticals, healthcare operations, and corporate restructuring. The leadership philosophy emphasizes operational execution, regulatory compliance, and long-term value creation through portfolio optimization and balance sheet improvement. Governance oversight is provided by a board with experience in healthcare, finance, and public company leadership.
Key executives include:
- Thomas J. Appio – Chief Executive Officer
- Paul Herendeen – Chief Financial Officer
- Joe Papa – Chairman of the Board
- David J. Meline – Former Chief Financial Officer and Board Member
- Amy L. Vanderslice – Chief Legal Officer
- Ethan H. C. Grover – President, Salix Pharmaceuticals
The leadership team’s strategic vision centers on stabilizing core businesses, maximizing the value of Bausch + Lomb, and strengthening the company’s financial position while maintaining focus on patient-centered healthcare solutions.